These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 36435945)

  • 21. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
    Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
    Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus.
    Ketaren NE; Mast FD; Fridy PC; Olivier JP; Sanyal T; Sali A; Chait BT; Rout MP; Aitchison JD
    bioRxiv; 2024 Jan; ():. PubMed ID: 37503298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants.
    Zhong J; Liu S; Cui T; Li J; Zhu F; Zhong N; Huang W; Zhao Z; Wang Z
    Emerg Microbes Infect; 2022 Dec; 11(1):2689-2697. PubMed ID: 36197655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants.
    Li T; Zhou B; Luo Z; Lai Y; Huang S; Zhou Y; Li Y; Gautam A; Bourgeau S; Wang S; Bao J; Tan J; Lavillette D; Li D
    Front Microbiol; 2022; 13():875840. PubMed ID: 35722331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the pathogenicity and neutrophil and monocyte response between SARS-CoV-2 prototype and Omicron BA.1 in a lethal mouse model.
    Rong N; Wu J; Zhao B; Peng W; Yang H; Zhang G; Ruan D; Wei X; Liu J
    Animal Model Exp Med; 2024 May; ():. PubMed ID: 38760905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
    Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menacherry V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
    bioRxiv; 2022 Mar; ():. PubMed ID: 33972947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
    Bruel T; Pinaud L; Tondeur L; Planas D; Staropoli I; Porrot F; Guivel-Benhassine F; Attia M; Pelleau S; Woudenberg T; Duru C; Koffi AD; Castelain S; Fernandes-Pellerin S; Jolly N; De Facci LP; Roux E; Ungeheuer MN; Van Der Werf S; White M; Schwartz O; Fontanet A
    EClinicalMedicine; 2022 Sep; 51():101576. PubMed ID: 35891947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants.
    Modhiran N; Lauer SM; Amarilla AA; Hewins P; Lopes van den Broek SI; Low YS; Thakur N; Liang B; Nieto GV; Jung J; Paramitha D; Isaacs A; Sng JDJ; Song D; Jørgensen JT; Cheuquemilla Y; Bürger J; Andersen IV; Himelreichs J; Jara R; MacLoughlin R; Miranda-Chacon Z; Chana-Cuevas P; Kramer V; Spahn C; Mielke T; Khromykh AA; Munro T; Jones ML; Young PR; Chappell K; Bailey D; Kjaer A; Herth MM; Jurado KA; Schwefel D; Rojas-Fernandez A; Watterson D
    iScience; 2023 Jul; 26(7):107085. PubMed ID: 37361875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.
    Zou J; Kurhade C; Xia H; Liu M; Xie X; Ren P; Shi PY
    Nat Commun; 2022 May; 13(1):2956. PubMed ID: 35618703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
    Güttler T; Aksu M; Dickmanns A; Stegmann KM; Gregor K; Rees R; Taxer W; Rymarenko O; Schünemann J; Dienemann C; Gunkel P; Mussil B; Krull J; Teichmann U; Groß U; Cordes VC; Dobbelstein M; Görlich D
    EMBO J; 2021 Oct; 40(19):e107985. PubMed ID: 34302370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel nanobody broadly neutralizes SARS-CoV-2 via induction of spike trimer dimers conformation.
    Yang Y; Zhang J; Zhang S; Zhang C; Shen C; Song S; Wang Y; Peng Y; Gong X; Dai J; Xie C; Khrustaleva TA; Khrustalev VV; Huo Y; Lu D; Yao D; Zhao J; Liu Y; Lu H
    Exploration (Beijing); 2024 Jun; 4(3):20230086. PubMed ID: 38939869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broad-Spectrum Engineered Multivalent Nanobodies Against SARS-CoV-1/2.
    Wang Z; Shi Z; Liao X; Quan G; Dong H; Zhao P; Zhou Y; Shi N; Wang J; Wu Y; Qiao C; Li XY; Zhang R; Wang Z; Wang T; Gao X; Feng J; Luo L
    Adv Sci (Weinh); 2024 Dec; 11(45):e2402975. PubMed ID: 39373693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins.
    Xu Y; Wu C; Cao X; Gu C; Liu H; Jiang M; Wang X; Yuan Q; Wu K; Liu J; Wang D; He X; Wang X; Deng SJ; Xu HE; Yin W
    Cell Res; 2022 Jul; 32(7):609-620. PubMed ID: 35641567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
    Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
    Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants.
    Yu B; Li S; Tabata T; Wang N; Cao L; Kumar GR; Sun W; Liu J; Ott M; Wang L
    Chem; 2022 Oct; 8(10):2766-2783. PubMed ID: 35874165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit.
    Qi X; Yang Y; Gong B; Li Z; Liang D
    J Thorac Dis; 2023 Sep; 15(9):4925-4937. PubMed ID: 37868850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.